“We delivered strong revenue growth in 2024 and significantly advanced our industry leading neuroscience pipeline, including achievement of positive Phase 3 results for AXS-05 in Alzheimer’s disease agitation and for AXS-12 in narcolepsy, supporting planned regulatory filings for these indications and products in 2025,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “We also look to carry our commercial momentum into 2025 with continued growth for Auvelity and Sunosi, and are making active launch preparations for AXS-07 for the acute treatment of migraine, if approved.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics price target raised to $180 from $150 at Truist
- Axsome Therapeutics price target raised to $140 from $138 at RBC Capital
- Top 3 Trending Stocks, According to Analysts – 1/2/2025
- Axsome Therapeutics price target lowered to $122 from $124 at Mizuho
- Axsome Therapeutics price target raised to $124 from $121 at Cantor Fitzgerald
Questions or Comments about the article? Write to editor@tipranks.com